JPRN-UMIN000007408RecruitingPhase 2
Phase II Trial of neoadjuvant chemotherapy with docetaxel, cisplatin and 5-FU for advanced esophageal cancer - Phase II Trial of neoadjuvant chemotherapy with DCF for esophageal cancer
Second Department of Surgery, Wakayama Medical University0 sites40 target enrollmentStarted: February 29, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Different histological type from squamous cell carcinoma or adenocarcinoma Patient with allergic response to anticancer drugs (docetaxel, cisplatin, 5-FU) Active or uncontrolled infection Pregnancy (women of childbearing potential: refusal or inability to use effective means of contraception) Clinically significant heart disease Patients with a history of myocardial infarction within the previous three months Patients with uncontrolled diabetes mellitus or hypertension Patients with interstitial pneumonia or pulmonary fibrosis Patients who receive hemodialysis Presence of clinically apparent central nervous system metastases Patients with any other severe concurrent disease, which in the judgment of the investigator, would make the patient inappropriate for entry into this study Decision of unsuitableness by principal investigator or physician-in-charge
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase II Study of Neoadjuvant Chemotherapy With Dose-Dense Paclitaxel In Association With Carboplatin followed by Radical Surgery for Locally Advanced Cervical Cancer (FIGO stage IB2- IIIA) Patients.EUCTR2016-003294-18-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI46
Completed
Phase 2
A Phase II study of Neoadjuvant chemotherapy in Docetaxel and Cyclophosphamide(TC therapy) with Operable HER2 Negative breast cancerbreast cancerJPRN-UMIN000013261Kyoto Prefectural University of Medicine50
Recruiting
Phase 2
Phase II study of the neoadjuvant chemotherapy of GEM/nab-PTX for biological borderline-resectable pancreatic cancerC535836pancreatic cancerJPRN-jRCT1041230068Ebata Tomoki50
Recruiting
Not Applicable
A phase II trial of neoadjuvant chemotherapy with docetaxel,cisplatin and S-1 (DCS) for radically resectable advanced gastric carcinoma (KDOG 1001)radically resectable advanced gastric carcinomaJPRN-UMIN000003642Kitasato University School of Medicine40
Recruiting
Phase 2
A phase II trial of neoadjuvant chemotherapy using the combination of gemcitabine and cisplatin for patients with initially unresectable locally advanced biliary tract cancer.Biliary tract cancer (Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma, Gallbladder carcinoma)JPRN-UMIN000015330Adjuvant therapy for BTC Research Group50